Fuller & Thaler Asset Management Inc. Buys 4,232 Shares of Amgen Inc. (NASDAQ:AMGN)

Fuller & Thaler Asset Management Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,971 shares of the medical research company's stock after purchasing an additional 4,232 shares during the period. Fuller & Thaler Asset Management Inc.'s holdings in Amgen were worth $9,636,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new position in shares of Amgen during the 4th quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in Amgen in the fourth quarter valued at approximately $34,000. Atala Financial Inc acquired a new position in shares of Amgen in the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the fourth quarter worth $36,000. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

AMGN traded up $1.15 during trading on Wednesday, hitting $289.71. 1,210,613 shares of the stock traded hands, compared to its average volume of 2,780,845. The business has a 50 day moving average price of $301.10 and a 200 day moving average price of $292.08. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a market cap of $155.76 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.29%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 126.09%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares in the company, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last quarter. Corporate insiders own 0.69% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMGN. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 17th. UBS Group upped their price objective on Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Piper Sandler boosted their target price on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Amgen currently has a consensus rating of "Hold" and a consensus target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.